Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study.

MLA

Ruscica, Massimiliano, et al. “Circulating PCSK9 as a Prognostic Biomarker of Cardiovascular Events in Individuals with Type 2 Diabetes: Evidence from a 16.8-Year Follow-up Study.” Cardiovascular Diabetology, vol. 22, no. 1, Aug. 2023, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s12933-023-01948-8.

APA

Ruscica, M., Macchi, C., Giuliani, A., Rizzuto, A. S., Ramini, D., Sbriscia, M., Carugo, S., Bonfigli, A. R., Corsini, A., Olivieri, F., & Sabbatinelli, J. (2023). Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study. Cardiovascular Diabetology, 22(1), 1–12. https://doi.org/10.1186/s12933-023-01948-8

Chicago

Ruscica, Massimiliano, Chiara Macchi, Angelica Giuliani, Alessandra Stefania Rizzuto, Deborah Ramini, Matilde Sbriscia, Stefano Carugo, et al. 2023. “Circulating PCSK9 as a Prognostic Biomarker of Cardiovascular Events in Individuals with Type 2 Diabetes: Evidence from a 16.8-Year Follow-up Study.” Cardiovascular Diabetology 22 (1): 1–12. doi:10.1186/s12933-023-01948-8.